Correlation Between Gut Microbiota and Pancreatic Β-Cell Function in Diabetic Patients
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Oct 15, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. Research Objective: This study aims to explore the differences in gut microbiota and their metabolites, as well as gene function differences, between young and elderly individuals under different glucose metabolism states. The goal is to screen for specific bacterial species or metabolites with significant differences and examine their correlation with pancreatic β-cell function.
2. Research Design
2.1 Study Subjects: Young and elderly subjects with different glucose metabolism states will be recruited from the community or the outpatient department of Peking University Third Hospital b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: Young (18 \< age \< 45 years) and elderly (age ≥ 65 years) subjects;
- • Individuals with different glucose metabolism states, including normal glucose metabolism, pre-diabetes, and diabetes, without gastrointestinal diseases or a history of gastrointestinal surgery (such as active gastrointestinal inflammation or bleeding, inflammatory bowel disease, etc.), without cognitive impairment, without tumors, and without chronic respiratory diseases (such as chronic obstructive pneumonia, asthma, etc.), and not on a special diet (e.g., vegetarians).
- Exclusion Criteria:
- • Use of antibiotics or health supplements within the last month.
- • Diarrhea within the last 2 weeks: bowel movements ≥3 times/24 hours, with changes in stool consistency.
- • Constipation within the last 2 weeks (based on the Rome III criteria for functional constipation).
- • Acute complications of diabetes, such as diabetic ketoacidosis, within the last 3 months.
- • History of gastrointestinal diseases or gastrointestinal surgery.
- • Cognitive impairment.
- • History of tumors.
- • Special diet (e.g., vegetarians).
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, Beijing, China
Beijing, , China
Patients applied
Trial Officials
Yang Jin
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported